Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy - A possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats?

Experimental and Toxicologic Pathology

Volumn 58, Issue 2-3, 2006, Pages 89-99

  Elangbam, Chandikumar S ^a   Wehe, John G ^b   Barton, Joanna C ^a   Krull, David L ^a   Nyska, Abraham ^c   Crabbs, Torrie ^b   Kissling, Grace E ^c  

^a GLAXOSMITHKLINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

5 hydroxytryptamine 2B receptor; Anorexigens; dl amphetamine; Fischer 344 rats; Mitral valve; Quantitative image analysis; Sprague Dawley rats; Valvulopathy

Indexed keywords

AMPHETAMINE; ANOREXIGENIC AGENT; GLYCOSAMINOGLYCAN; SEROTONIN 2B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FEMALE; MALE; MITRAL VALVE; MORPHOLOGY; NONHUMAN; PATHOGENESIS; PREVALENCE; RAT; VALVULAR HEART DISEASE;

EID: 33750379825     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2006.08.001     Document Type: Article

References (37)

1. Angrist A., Oka M., Nakao K., and Marquiss J. Studies on experimental endocarditis: 1. Production of valvular lesions by mechanisms not involving infection or sensitivity factors. Am J Pathol 36 (1960) 181-199
2. Caccitolo J.A., Connolly H.M., Rubenson D.S., Orszulak T.A., and Schaff H.V. Operation for anorexigen-associated valvular heart disease. J Thorac Cardiovasc Surg 122 (2001) 656-664
3. Carabello B.A., and Crawford F.A. Valvular heart disease. N Engl J Med 337 (1997) 32-41
4. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwahrds B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
5. Elangbam C.S., Colman K.A., Lightfoot R.M., Tyler R.D., and Wall H.G. Endocardial myxomatous change in Harlan Sprague-Dawley rats (Hsd:S-D) and CD-1 mice: its microscopic resemblance to drug-induced valvulopathy in humans. Toxicol Pathol 30 (2002) 483-491
6. Elangbam C.S., Lightfoot R.M., Yoon L.W., Creech D.R., Geske R.S., Crumbley C.W., et al. 5-Hydroxytryptamine (5HT) receptors in the heart valves of Cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53 (2005) 671-677
7. Fanburg B.L., and Lee S.L. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272 (1997) L795-L806
8. Findling R.L., Biederman J., Wilens T.E., Spencer T.J., McGough J.J., et al., and on behalf of the SLI381.301 and .302 study groups. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 147 (2005) 348-354
9. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57 (2000) 75-81
10. Gross M.D. A comparison of dextroamphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction. Dis Nerv Syst 37 (1976) 14-16
11. Gustafsson B.I., Tommeras K., Nordrum I., Loennechen J.P., Brunsvik A., Solligard E., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
12. Gutgesell H., Atkins D., Barst R., Buck M., Franklin W., Humes R., et al. AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38 (1999) 1047-1050
13. Hoffman B.B. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed (2001), McGraw-Hill Medical Publishing Division 215-268
14. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement Disord 19 (2004) 656-662
15. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., and Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339 (1998) 719-724
16. Kimball S.R., O'Malley J.P., Anthony J.C., Crozier S.J., and Jefferson L.S. Assessment of biomarkers of protein anabolism in skeletal muscle during the life span of the rat: sarcopenia despite elevated protein synthesis. Am J Physiol-Endocrinol Metab 287 (2004) 772-780
17. McDonald P.C., Wilson J.E., Gao M., McNeill S., Spinelli J.J., Williams O.D., et al. Quantitative analysis of human heart valves - does anorexigen exposure produce a distinctive morphological lesion?. Cardiovasc Pathol 11 (2002) 251-262
18. McDonald P.C., Wilson J.E., Gao M., Spinelli J.J., Wiebe H., McNeill S., et al. The challenge of defining normality of human mitral and aortic valves: geometrical and compositional analysis. Cardiovasc Pathol 11 (2002) 193-209
19. Milroy C.M., Clark J.C., and Forrest A.R.W. Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol 49 (1996) 149-153
20. National Toxicology Program. NTP Technical report on the toxicology and carcinogenesis studies of dl-amphetamine sulfate (CAS no. 60-13-9) in F344/N rats and B6C3F1 mice (Feed Studies), NTP TR-387, NIEHS, Research Triangle Park, NC, 1991. 〈http://ntp-server.niehs.nih.gov/index〉.
21. Nebigil C.G., and Maroteaux L. Functional consequence of serotonin/5-HT2B receptor signaling in heart. Role of mitochondria in transition between hypertrophy and heart failure?. Circulation 108 (2003) 902
22. Nebigil C.G., Hickel P., Messaddeq N., Vonesch J.L., Douchet M.P., Monassier L., et al. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation 103 (2001) 2973-2979
23. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verriele L., Carpentier N., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2 receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
24. Pritchett A.M., Morrison J.F., Edwards W.D., Schaff H.V., Connolly H.M., and Espinosa R.E. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 (2002) 1280-1286
25. Rajamannan N.M., Caplice N., Anthikad F., Sebo T.J., Orszulak T.A., Edwards W.D., et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10 (2001) 827-831
26. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
27. Ruben Z, Arceo RJ, Bishop SP, Elwell MR, Kerns WD, Mesfin GM, et al. Non-proliferative lesions of the heart and vasculature in rats. CV-1. In: Guides for toxicologic pathology STP/ARP/AFIP. Washington DC; 2000. p. 1-10.
28. Sari Y., and Zhou F.C. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 21 (2003) 417-424
29. Schenk K.E., and Heinze G. Age-dependent changes of heart valves and heart size. Recent Adv Stud Cardiac Struct Metab 10 (1975) 617-624
30. Setola V., Hufeisen S.J., Grande-Allen K.J., Vesely I., Glennon R.A., Blough B., et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63 (2003) 1223-1229
31. Sheehan D.C., and Hrapchak B.B. Theory and practice of histotechnology. 2nd ed (1980), Battelle Press, Columbus p. 180-201
32. Simula D.V., Edwards W.D., Tazelaar H.D., Connolly H.M., and Schaff H.V. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77 (2002) 139-147
33. Steffee C.H., Singh H.K., and Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8 (1999) 245-253
34. Van Camp G., Flamez A., Cosyns B., Weytjens C., Muyldermans L., Van Zandijcke M., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 (2004) 1179-1183
35. Volmar K.E., and Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125 (2001) 1555-1561
36. Weiss B., and Laties V.G. Enhancement of human performance by caffeine and the amphetamines. Pharmacol Rev 14 (1962) 1-36
37. Weissman N.J. Appetite suppressants and valvular heart disease. Am J Med Sci 321 (2001) 285-291